<html>
  <head>
    <title>ChatGPT Data Export</title>
    <style>
      body {
        margin: 20px;
      }
      h4 {
        font-family: sans-serif;
        margin: 0;
      }
      #root {
        display: flex;
        flex-direction: column;
        gap: 20px;
      }
      .conversation {
        border: 1px solid black;
        padding: 20px;
        background-color: #f3f3f3;
      }
      .message {
        white-space: pre-wrap;
        margin: 20px 0;
      }
      .author {
        font-weight: bold;
        margin-bottom: 4px;
      }
      .author::first-letter {
        text-transform: uppercase;
      }
    </style>
    <script>
      var jsonData = [{"title":"GPT-4 Translation 1","create_time":1697402536.141588,"update_time":1697402720.821012,"mapping":{"32cd1bc2-c599-49cc-90d2-10d40d596d84":{"id":"32cd1bc2-c599-49cc-90d2-10d40d596d84","message":{"id":"32cd1bc2-c599-49cc-90d2-10d40d596d84","author":{"role":"system","name":null,"metadata":{}},"create_time":null,"update_time":null,"content":{"content_type":"text","parts":[""]},"status":"finished_successfully","end_turn":true,"weight":0,"metadata":{},"recipient":"all"},"parent":"aaa1861d-2997-4ce4-9bb0-1abccd9585cf","children":["aaa2ea49-17b2-471e-91d3-102112fd7ffd"]},"aaa1861d-2997-4ce4-9bb0-1abccd9585cf":{"id":"aaa1861d-2997-4ce4-9bb0-1abccd9585cf","message":null,"parent":null,"children":["32cd1bc2-c599-49cc-90d2-10d40d596d84"]},"aaa2ea49-17b2-471e-91d3-102112fd7ffd":{"id":"aaa2ea49-17b2-471e-91d3-102112fd7ffd","message":{"id":"aaa2ea49-17b2-471e-91d3-102112fd7ffd","author":{"role":"user","name":null,"metadata":{}},"create_time":1697402536.143176,"update_time":null,"content":{"content_type":"text","parts":["# Introduction\n\nI would like you to act as a translation committee who is working on translating technical clinical trials related text to plain language for general public. This committee consists of 3 members, which are described under the heading \"Agents\". These agents use predefined workflows to translate the text under the heading \"Text for translation\". Please start with \"English Language Expert\" executing the \"Initial translation workflow\". \n\nWhile executing the workflows only output the following:\n\n```\n# <Agent> - <Workflow>\n\nJSON formatted output\n\n# <Agent> - <Workflow>\n\nJSON formatted output\n\n# Final translation\n\nJSON formatted output\n```\n\n# Agents\n\n## English Language Expert\n\nYou are an English Language Expert who is specialised in translating technical clinical trials texts to plain language. You are well versed in English language, translation, and medical terminology. Your goal is to make these texts accessible for participants, their families, and the general public.\n\n## Public Consultant\n\nYou're a Public Consultant skilled in public communication. Your task is to review translations from the Language Expert, ensuring they're clear, relatable, and accessible. You'll offer feedback to make sure the content is easily understood by the general public, including participants and their families, and suggest changes if needed.\n\n## Project Manager\n\nYou are a Project Manager with experience in overseeing translation and communication projects within the healthcare sector. Your role is to manage the translation process, ensuring it stays on track and meets the established criteria of accuracy, clarity, and timeliness. You assess the outputs from both the English Language Expert and the Public Consultant, and decide if the translations are ready for dissemination or if further revisions are needed.\n\n# Predefined workflows\n\n## Initial translation workflow\n\n1. Take a deep breath and work on this task step by step.\n2. Check the \"Text for Translation\" to identify technical terms and create a list of these terms.\n3. Translate the text into plain language to make it accessible for the general public especially focusing on technical terms identified in the previous step.\n4. Check if it would be helpful to provide some technical term translations in brackets, especially when the patient might be familiar with the technical name and it's in patient's interest to provide the the technical term, e.g., \"hypertension (high blood pressure)\".\n5. Check the translation for phrasal verbs and replace them where possible.\n6. Avoid being verbose. Try not to exceed the length of the original text.\n7. The translation should maintain the accurate meaning of the original text, not to add or omit any essential details.\n8. Finally check the translation again for coherence. If you think that your translation doesn't successfully fulfil any of the steps above, iterate over it until you think that you met all the criteria.\n9. When you are happy with the translation, create a json formatted output as follows: `{\"translation\": <translation>}`.\n10. Ask \"Public Consultant\" to carry on with the \"Translation feedback workflow\".\n\n## Translation feedback workflow\n\n1. Take a deep breath and work on this task step by step.\n2. Reach out to \"English Language Expert\" for the translation.\n3. Assess the text carefully and create a feedback using bullet points to highlight the accessibility issues within the translation.\n4. Along with the feedback, draft a text that demonstrates what you have understood from the translation and how you interpreted it.\n5. Create a JSON formatted output as follows: `{\"consultant_feedback\": [<bullet_point_1>, <bullet_point_2>], \"interpretation\": <interpretation>}`.\n6. Ask \"Project Manager\" to carry on with the \"Translation and feedback assessment workflow\".\n\n## Translation and feedback assessment workflow\n\n1. Take a deep breath and work on this task step by step.\n2. Start with checking the \"Text for Translation\".\n3. Reach out to the \"English Language Expert\" to get the \"Initial translation workflow\" output.\n4. Reach out to the \"Public consultant\" to get the \"Translation feedback workflow\" output.\n5. Considering the \"Text for Translation\" and the outputs above assess the quality of the translation for coherence and accessibility. \n6. If you are not happy with the translation, create a feedback  in JSON format summarising all issues noticed by you and the \"Public consultant\" as follows: `{\"pm_feedback\": <summarised_feedback>}` .\n7. Ask \"English Language Expert\" to carry on  with the \"Translation improvement workflow\".\n8. If you are happy with the translation create a final output and finalise the process as follows: `{\"final_output\": <final_output>}`.\n\n## Translation improvement workflow\n\n1. Take a deep breath and work on this task step by step.\n2. Start by checking the 'Text for Translation' and your previous translation.\n3. Reach out to the \"Project Manager\" to get the \"Translation and feedback assessment workflow\" output.\n4. Considering the given feedback and your Initial translation workflow, improve your former translation.\n5. Double check your work to see if all feedback were assessed.\n6. If you think that your translation doesn't successfully fulfil any of the steps above, iterate over it until you think that you met all the criteria.\n7. When you are happy with the translation, create a json formatted output as follows: `{\"translation\": <translation>}.\n8. Ask \"Public Consultant\" to carry on with the \"Translation feedback workflow\".\n\n# Text for translation\n\nThis trial is designed to characterize the clinical course of women with small, node negative breast cancer who are treated with a uniform trastuzumab-containing regimen. The inclusion criteria specifically target women who were generally not eligible for previous trials with HER2-directed therapy. Ideally, a randomized controlled trial would be conducted in this population to compare the utility of treatment with trastuzumab in combination with paclitaxel compared to paclitaxel alone, but such a trial would require many thousands of patients, and it is not believed feasible to enroll a sufficient number of patients in a reasonable time period in order to accomplish such a trial. For that matter, based on discussions with oncologists and breast cancer advocates, it seems unlikely that physicians and patients would be comfortable with the randomization."]},"status":"finished_successfully","end_turn":null,"weight":1,"metadata":{"timestamp_":"absolute","message_type":null},"recipient":"all"},"parent":"32cd1bc2-c599-49cc-90d2-10d40d596d84","children":["1293038c-6fd6-4a76-b078-4d291c21434a"]},"1293038c-6fd6-4a76-b078-4d291c21434a":{"id":"1293038c-6fd6-4a76-b078-4d291c21434a","message":{"id":"1293038c-6fd6-4a76-b078-4d291c21434a","author":{"role":"assistant","name":null,"metadata":{}},"create_time":1697402591.492268,"update_time":null,"content":{"content_type":"text","parts":["# English Language Expert - Initial translation workflow\n\n```json\n{\n  \"translation\": \"This study aims to understand how a specific treatment affects women with a small type of breast cancer that hasn't spread to nearby lymph nodes. We are focusing on women who couldn't join earlier studies for treatments targeting the HER2 protein in cancer cells. Ideally, we'd have a big study where we compare this specific treatment combined with another drug, paclitaxel, to just using paclitaxel. But, such a large study would need a lot of participants and would be tough to set up quickly. Also, based on what cancer specialists and advocates say, doctors and patients might not be okay with being randomly picked for one treatment or the other.\"\n}\n```\n\n# Public Consultant - Translation feedback workflow\n\n```json\n{\n  \"consultant_feedback\": [\n    \"Consider simplifying 'a specific treatment' to name the treatment directly.\",\n    \"Explain the term 'HER2 protein' briefly, as the general public might not be familiar.\",\n    \"The term 'randomly picked' could be replaced with 'assigned randomly' for clarity.\"\n  ],\n  \"interpretation\": \"The study is about seeing the effects of a treatment on women with a small type of breast cancer. This study focuses on a group of women who weren't part of older studies. They ideally wanted to compare this treatment with another drug but decided it would be too big and difficult to do. Also, some doctors and patients might not be okay with how they decide who gets which treatment.\"\n}\n```\n\n# Project Manager - Translation and feedback assessment workflow\n\n```json\n{\n  \"pm_feedback\": \"The translation captures the essence of the original text, but there are a few areas of improvement highlighted by the Public Consultant. Specifically, naming the treatment directly would aid clarity. Also, providing a short description of the 'HER2 protein' and refining the term 'assigned randomly' would enhance understanding for the general audience. It's suggested to revise the translation considering this feedback.\"\n}\n```\n\n# English Language Expert - Translation improvement workflow\n\n```json\n{\n  \"translation\": \"This study aims to see the effects of trastuzumab treatment on women with a specific small type of breast cancer that hasn't spread to nearby areas. We're focusing on women who weren't part of earlier studies for treatments aimed at the HER2 protein in cancer (a protein that can help cancer cells grow). Ideally, we'd compare trastuzumab combined with the drug paclitaxel to just using paclitaxel. But, a study like that would need many participants and would take a long time to set up. Plus, based on feedback from cancer experts and supporters, doctors and patients might not be okay with being assigned randomly to a treatment.\"\n}\n```\n\n# Public Consultant - Translation feedback workflow\n\n```json\n{\n  \"consultant_feedback\": [\n    \"The explanation of 'HER2 protein' is helpful and clarifies the concept.\",\n    \"The revision on 'assigned randomly' is clearer now.\"\n  ],\n  \"interpretation\": \"The study is to understand how trastuzumab, a treatment, affects women with a specific kind of small breast cancer. The study is especially for women who weren't in past studies focused on a certain protein in cancer called HER2. The plan was to see if combining trastuzumab with another drug, paclitaxel, is better than using just paclitaxel. But, this would need a big study, and setting it up would be a challenge. Also, doctors and patients might not like the idea of being assigned a treatment by chance.\"\n}\n```\n\n# Project Manager - Translation and feedback assessment workflow\n\n```json\n{\n  \"final_output\": \"This study aims to see the effects of trastuzumab treatment on women with a specific small type of breast cancer that hasn't spread to nearby areas. We're focusing on women who weren't part of earlier studies for treatments aimed at the HER2 protein in cancer (a protein that can help cancer cells grow). Ideally, we'd compare trastuzumab combined with the drug paclitaxel to just using paclitaxel. But, a study like that would need many participants and would take a long time to set up. Plus, based on feedback from cancer experts and supporters, doctors and patients might not be okay with being assigned randomly to a treatment.\"\n}\n```"]},"status":"finished_successfully","end_turn":true,"weight":1,"metadata":{"finish_details":{"type":"stop","stop_tokens":[100260]},"is_complete":true,"message_type":null,"model_slug":"gpt-4","parent_id":"aaa2ea49-17b2-471e-91d3-102112fd7ffd","timestamp_":"absolute"},"recipient":"all"},"parent":"aaa2ea49-17b2-471e-91d3-102112fd7ffd","children":[]}},"moderation_results":[],"current_node":"1293038c-6fd6-4a76-b078-4d291c21434a","plugin_ids":null,"conversation_id":"9c5d3bea-caf2-415b-a5f1-363dbc259bdf","conversation_template_id":null,"gizmo_id":null,"id":"9c5d3bea-caf2-415b-a5f1-363dbc259bdf"},{"title":"GPT-4 Translation 2","create_time":1697402774.426495,"update_time":1697402987.776209,"mapping":{"efc1d3fa-b9e4-49f4-aba7-e0bb876399b5":{"id":"efc1d3fa-b9e4-49f4-aba7-e0bb876399b5","message":{"id":"efc1d3fa-b9e4-49f4-aba7-e0bb876399b5","author":{"role":"system","name":null,"metadata":{}},"create_time":null,"update_time":null,"content":{"content_type":"text","parts":[""]},"status":"finished_successfully","end_turn":true,"weight":0,"metadata":{},"recipient":"all"},"parent":"aaa171e5-9d41-4082-a025-401946fc0483","children":["aaa25666-f548-433c-b956-f8d2d3d51b8d"]},"aaa171e5-9d41-4082-a025-401946fc0483":{"id":"aaa171e5-9d41-4082-a025-401946fc0483","message":null,"parent":null,"children":["efc1d3fa-b9e4-49f4-aba7-e0bb876399b5"]},"aaa25666-f548-433c-b956-f8d2d3d51b8d":{"id":"aaa25666-f548-433c-b956-f8d2d3d51b8d","message":{"id":"aaa25666-f548-433c-b956-f8d2d3d51b8d","author":{"role":"user","name":null,"metadata":{}},"create_time":1697402774.427708,"update_time":null,"content":{"content_type":"text","parts":["# Introduction\n\nI would like you to act as a translation committee who is working on translating technical clinical trials related text to plain language for general public. This committee consists of 3 members, which are described under the heading \"Agents\". These agents use predefined workflows to translate the text under the heading \"Text for translation\". Please start with \"English Language Expert\" executing the \"Initial translation workflow\". \n\nWhile executing the workflows only output the following:\n\n```\n# <Agent> - <Workflow>\n\nJSON formatted output\n\n# <Agent> - <Workflow>\n\nJSON formatted output\n\n# Final translation\n\nJSON formatted output\n```\n\n# Agents\n\n## English Language Expert\n\nYou are an English Language Expert who is specialised in translating technical clinical trials texts to plain language. You are well versed in English language, translation, and medical terminology. Your goal is to make these texts accessible for participants, their families, and the general public.\n\n## Public Consultant\n\nYou're a Public Consultant skilled in public communication. Your task is to review translations from the Language Expert, ensuring they're clear, relatable, and accessible. You'll offer feedback to make sure the content is easily understood by the general public, including participants and their families, and suggest changes if needed.\n\n## Project Manager\n\nYou are a Project Manager with experience in overseeing translation and communication projects within the healthcare sector. Your role is to manage the translation process, ensuring it stays on track and meets the established criteria of accuracy, clarity, and timeliness. You assess the outputs from both the English Language Expert and the Public Consultant, and decide if the translations are ready for dissemination or if further revisions are needed.\n\n# Predefined workflows\n\n## Initial translation workflow\n\n1. Take a deep breath and work on this task step by step.\n2. Check the \"Text for Translation\" to identify technical terms and create a list of these terms.\n3. Translate the text into plain language to make it accessible for the general public especially focusing on technical terms identified in the previous step.\n4. Check if it would be helpful to provide some technical term translations in brackets, especially when the patient might be familiar with the technical name and it's in patient's interest to provide the the technical term, e.g., \"hypertension (high blood pressure)\".\n5. Check the translation for phrasal verbs and replace them where possible.\n6. Avoid being verbose. Try not to exceed the length of the original text.\n7. The translation should maintain the accurate meaning of the original text, not to add or omit any essential details.\n8. Finally check the translation again for coherence. If you think that your translation doesn't successfully fulfil any of the steps above, iterate over it until you think that you met all the criteria.\n9. When you are happy with the translation, create a json formatted output as follows: `{\"translation\": <translation>}`.\n10. Ask \"Public Consultant\" to carry on with the \"Translation feedback workflow\".\n\n## Translation feedback workflow\n\n1. Take a deep breath and work on this task step by step.\n2. Reach out to \"English Language Expert\" for the translation.\n3. Assess the text carefully and create a feedback using bullet points to highlight the accessibility issues within the translation.\n4. Along with the feedback, draft a text that demonstrates what you have understood from the translation and how you interpreted it.\n5. Create a JSON formatted output as follows: `{\"consultant_feedback\": [<bullet_point_1>, <bullet_point_2>], \"interpretation\": <interpretation>}`.\n6. Ask \"Project Manager\" to carry on with the \"Translation and feedback assessment workflow\".\n\n## Translation and feedback assessment workflow\n\n1. Take a deep breath and work on this task step by step.\n2. Start with checking the \"Text for Translation\".\n3. Reach out to the \"English Language Expert\" to get the \"Initial translation workflow\" output.\n4. Reach out to the \"Public consultant\" to get the \"Translation feedback workflow\" output.\n5. Considering the \"Text for Translation\" and the outputs above assess the quality of the translation for coherence and accessibility. \n6. If you are not happy with the translation, create a feedback  in JSON format summarising all issues noticed by you and the \"Public consultant\" as follows: `{\"pm_feedback\": <summarised_feedback>}` .\n7. Ask \"English Language Expert\" to carry on  with the \"Translation improvement workflow\".\n8. If you are happy with the translation create a final output and finalise the process as follows: `{\"final_output\": <final_output>}`.\n\n## Translation improvement workflow\n\n1. Take a deep breath and work on this task step by step.\n2. Start by checking the 'Text for Translation' and your previous translation.\n3. Reach out to the \"Project Manager\" to get the \"Translation and feedback assessment workflow\" output.\n4. Considering the given feedback and your Initial translation workflow, improve your former translation.\n5. Double check your work to see if all feedback were assessed.\n6. If you think that your translation doesn't successfully fulfil any of the steps above, iterate over it until you think that you met all the criteria.\n7. When you are happy with the translation, create a json formatted output as follows: `{\"translation\": <translation>}.\n8. Ask \"Public Consultant\" to carry on with the \"Translation feedback workflow\".\n\n# Text for translation\n\nMost adjuvant trastuzumab trials administered trastuzumab for 52 weeks of treatment. The small but provocative FinHER trial included only 232 patients, but administered only 9 weeks of trastuzumab paired with taxane therapy. This study demonstrated relative risk reduction of >50% for the use of trastuzumab, suggesting indirectly that concurrent taxane- trastuzumab therapy can be effective treatment for early stage breast cancer and is superior to taxane-anthracycline chemotherapy given in the absence of trastuzumab. Preliminary analyses of NCCTG N9831 suggest that concurrent use of taxane-trastuzumab therapy is superior to sequential use, further justifying a combination treatment program."]},"status":"finished_successfully","end_turn":null,"weight":1,"metadata":{"timestamp_":"absolute","message_type":null},"recipient":"all"},"parent":"efc1d3fa-b9e4-49f4-aba7-e0bb876399b5","children":["18000527-0f8e-4683-bb6e-b37aff398426"]},"18000527-0f8e-4683-bb6e-b37aff398426":{"id":"18000527-0f8e-4683-bb6e-b37aff398426","message":{"id":"18000527-0f8e-4683-bb6e-b37aff398426","author":{"role":"assistant","name":null,"metadata":{}},"create_time":1697402866.734633,"update_time":null,"content":{"content_type":"text","parts":["# English Language Expert - Initial translation workflow\n\nLet's start the initial translation process:\n\n1. I took a deep breath.\n2. Identified technical terms:\n   - adjuvant\n   - trastuzumab\n   - FinHER trial\n   - taxane therapy\n   - relative risk reduction\n   - taxane-anthracycline chemotherapy\n   - NCCTG N9831\n   - sequential use\n   - concurrent use\n3. Initial translation:\n   Most studies that used the additional trastuzumab treatment provided it for 52 weeks. The smaller FinHER study had only 232 patients and used trastuzumab for just 9 weeks along with another treatment called taxane. This study showed that using trastuzumab can cut the risk by more than half, hinting that using taxane and trastuzumab at the same time can effectively treat early stage breast cancer. It seems better than using taxane with another treatment called anthracycline when trastuzumab isn't included. Early results from another study called NCCTG N9831 suggest that using taxane and trastuzumab together at the same time is better than using them one after the other, further supporting the idea of using them in combination.\n4. Adjusted for technical terms in brackets:\n   Most studies that used the additional trastuzumab treatment (a kind of medication) provided it for 52 weeks. The smaller FinHER study had only 232 patients and used trastuzumab for just 9 weeks along with another treatment called taxane. This study showed that using trastuzumab can cut the risk by more than half, hinting that using taxane and trastuzumab at the same time can effectively treat early stage breast cancer. It seems better than using taxane with another treatment called anthracycline when trastuzumab isn't included. Early results from another study called NCCTG N9831 suggest that using taxane and trastuzumab together at the same time is better than using them one after the other, further supporting the idea of using them in combination.\n5. Checked for phrasal verbs and replaced them.\n6. Ensured the length was not too verbose.\n7. Made sure the translation maintains the original meaning without omitting details.\n8. Checked the translation for coherence.\n\nJSON formatted output:\n\n```json\n{\n  \"translation\": \"Most studies that used the additional trastuzumab treatment (a kind of medication) provided it for 52 weeks. The smaller FinHER study had only 232 patients and used trastuzumab for just 9 weeks along with another treatment called taxane. This study showed that using trastuzumab can cut the risk by more than half, hinting that using taxane and trastuzumab at the same time can effectively treat early stage breast cancer. It seems better than using taxane with another treatment called anthracycline when trastuzumab isn't included. Early results from another study called NCCTG N9831 suggest that using taxane and trastuzumab together at the same time is better than using them one after the other, further supporting the idea of using them in combination.\"\n}\n```\n\n# Public Consultant - Translation feedback workflow\n\n1. Took a deep breath.\n2. Retrieved the translation from \"English Language Expert\".\n3. Assessed the text and identified potential accessibility issues.\n4. Feedback:\n   - The term \"additional trastuzumab treatment\" might be confusing. Why \"additional\"?\n   - The use of \"hinting\" may not be clear enough for some readers. Can we say \"indicating\" or \"showing\" instead?\n   - The phrase \"using them in combination\" is clearer if we specify what \"them\" refers to.\n5. Drafted an interpretation of the translation.\n6. JSON formatted output:\n\n```json\n{\n  \"consultant_feedback\": [\n    \"The term 'additional trastuzumab treatment' might be confusing. Why 'additional'?\",\n    \"The use of 'hinting' may not be clear enough for some readers. Can we say 'indicating' or 'showing' instead?\",\n    \"The phrase 'using them in combination' is clearer if we specify what 'them' refers to.\"\n  ],\n  \"interpretation\": \"Most research that used trastuzumab, a type of medication, gave it for 52 weeks. The smaller FinHER study tested it on 232 patients for 9 weeks with a treatment named taxane. They found trastuzumab reduces risk by over half, suggesting that combining taxane and trastuzumab can be a good treatment for early breast cancer. It appears more effective than mixing taxane with another drug called anthracycline without trastuzumab. Another study, NCCTG N9831, indicates that giving taxane and trastuzumab at the same time works better than giving them separately, further supporting the idea of combining these treatments.\"\n}\n```\n\n# Project Manager - Translation and feedback assessment workflow\n\n1. Took a deep breath.\n2. Checked the \"Text for Translation\".\n3. Retrieved the translation from \"English Language Expert\".\n4. Retrieved feedback and interpretation from \"Public consultant\".\n5. After analyzing all the data, there are areas for improvement in the translation for better coherence and accessibility.\n6. JSON formatted feedback:\n\n```json\n{\n  \"pm_feedback\": \"The translation provided is largely accessible, but a few points highlighted by the Public Consultant require attention for clarity. Specifically, the term 'additional', the use of the word 'hinting', and the clarity on what 'them' refers to in 'using them in combination'.\"\n}\n```\n\n# English Language Expert - Translation improvement workflow\n\n1. Took a deep breath.\n2. Checked the 'Text for Translation' and the previous translation.\n3. Retrieved feedback from the \"Project Manager\".\n4. Improved the translation considering the feedback.\n5. Checked if all feedback was addressed.\n6. JSON formatted output:\n\n```json\n{\n  \"translation\": \"Most research that used trastuzumab, a type of medication, gave it for 52 weeks. The smaller FinHER study tested it on 232 patients for 9 weeks alongside a treatment named taxane. This study found that trastuzumab reduces risk by more than half, indicating that using taxane and trastuzumab together can effectively treat early stage breast cancer. This combination seems more effective than mixing taxane with another drug called anthracycline without trastuzumab. Another study, NCCTG N9831, shows that giving both taxane and trastuzumab at the same time is better than giving them one after the other, further supporting the idea of combining these two treatments.\"\n}\n```\n\n# Final translation\n\n```json\n{\n  \"final_output\": \"Most research that used trastuzumab, a type of medication, gave it for 52 weeks. The smaller FinHER study tested it on 232 patients for 9 weeks alongside a treatment named taxane. This study found that trastuzumab reduces risk by more than half, indicating that using taxane and trastuzumab together can effectively treat early stage breast cancer. This combination seems more effective than mixing taxane with another drug called anthracycline without trast"]},"status":"finished_partial_completion","end_turn":false,"weight":1,"metadata":{"finish_details":{"type":"max_tokens"},"is_complete":true,"message_type":null,"model_slug":"gpt-4","parent_id":"aaa25666-f548-433c-b956-f8d2d3d51b8d","timestamp_":"absolute"},"recipient":"all"},"parent":"aaa25666-f548-433c-b956-f8d2d3d51b8d","children":["22d19a7e-d759-4d3f-9388-b66496a9539a"]},"22d19a7e-d759-4d3f-9388-b66496a9539a":{"id":"22d19a7e-d759-4d3f-9388-b66496a9539a","message":{"id":"22d19a7e-d759-4d3f-9388-b66496a9539a","author":{"role":"assistant","name":null,"metadata":{}},"create_time":1697402934.962904,"update_time":null,"content":{"content_type":"text","parts":["uzumab. Another study, NCCTG N9831, shows that giving both taxane and trastuzumab at the same time is better than giving them one after the other, further supporting the idea of combining these two treatments.\"\n}\n```"]},"status":"finished_successfully","end_turn":true,"weight":1,"metadata":{"finish_details":{"type":"stop","stop_tokens":[100260]},"is_complete":true,"message_type":null,"model_slug":"gpt-4","parent_id":"18000527-0f8e-4683-bb6e-b37aff398426","timestamp_":"absolute"},"recipient":"all"},"parent":"18000527-0f8e-4683-bb6e-b37aff398426","children":[]}},"moderation_results":[],"current_node":"22d19a7e-d759-4d3f-9388-b66496a9539a","plugin_ids":null,"conversation_id":"30956fb0-523a-43b8-a03c-76e16ad4de80","conversation_template_id":null,"gizmo_id":null,"id":"30956fb0-523a-43b8-a03c-76e16ad4de80"},{"title":"GPT-4 Translation 3","create_time":1697403027.127315,"update_time":1697403240.035325,"mapping":{"4c011fca-1ecc-4667-a601-262d42de784b":{"id":"4c011fca-1ecc-4667-a601-262d42de784b","message":{"id":"4c011fca-1ecc-4667-a601-262d42de784b","author":{"role":"system","name":null,"metadata":{}},"create_time":null,"update_time":null,"content":{"content_type":"text","parts":[""]},"status":"finished_successfully","end_turn":true,"weight":0,"metadata":{},"recipient":"all"},"parent":"aaa10229-a921-4c0c-91cd-bc35d46830a6","children":["aaa23991-63ef-4782-aa56-a0fdeb7fc5a5"]},"aaa10229-a921-4c0c-91cd-bc35d46830a6":{"id":"aaa10229-a921-4c0c-91cd-bc35d46830a6","message":null,"parent":null,"children":["4c011fca-1ecc-4667-a601-262d42de784b"]},"aaa23991-63ef-4782-aa56-a0fdeb7fc5a5":{"id":"aaa23991-63ef-4782-aa56-a0fdeb7fc5a5","message":{"id":"aaa23991-63ef-4782-aa56-a0fdeb7fc5a5","author":{"role":"user","name":null,"metadata":{}},"create_time":1697403027.128734,"update_time":null,"content":{"content_type":"text","parts":["# Introduction\n\nI would like you to act as a translation committee who is working on translating technical clinical trials related text to plain language for general public. This committee consists of 3 members, which are described under the heading \"Agents\". These agents use predefined workflows to translate the text under the heading \"Text for translation\". Please start with \"English Language Expert\" executing the \"Initial translation workflow\". \n\nWhile executing the workflows only output the following:\n\n```\n# <Agent> - <Workflow>\n\nJSON formatted output\n\n# <Agent> - <Workflow>\n\nJSON formatted output\n\n# Final translation\n\nJSON formatted output\n```\n\n# Agents\n\n## English Language Expert\n\nYou are an English Language Expert who is specialised in translating technical clinical trials texts to plain language. You are well versed in English language, translation, and medical terminology. Your goal is to make these texts accessible for participants, their families, and the general public.\n\n## Public Consultant\n\nYou're a Public Consultant skilled in public communication. Your task is to review translations from the Language Expert, ensuring they're clear, relatable, and accessible. You'll offer feedback to make sure the content is easily understood by the general public, including participants and their families, and suggest changes if needed.\n\n## Project Manager\n\nYou are a Project Manager with experience in overseeing translation and communication projects within the healthcare sector. Your role is to manage the translation process, ensuring it stays on track and meets the established criteria of accuracy, clarity, and timeliness. You assess the outputs from both the English Language Expert and the Public Consultant, and decide if the translations are ready for dissemination or if further revisions are needed.\n\n# Predefined workflows\n\n## Initial translation workflow\n\n1. Take a deep breath and work on this task step by step.\n2. Check the \"Text for Translation\" to identify technical terms and create a list of these terms.\n3. Translate the text into plain language to make it accessible for the general public especially focusing on technical terms identified in the previous step.\n4. Check if it would be helpful to provide some technical term translations in brackets, especially when the patient might be familiar with the technical name and it's in patient's interest to provide the the technical term, e.g., \"hypertension (high blood pressure)\".\n5. Check the translation for phrasal verbs and replace them where possible.\n6. Avoid being verbose. Try not to exceed the length of the original text.\n7. The translation should maintain the accurate meaning of the original text, not to add or omit any essential details.\n8. Finally check the translation again for coherence. If you think that your translation doesn't successfully fulfil any of the steps above, iterate over it until you think that you met all the criteria.\n9. When you are happy with the translation, create a json formatted output as follows: `{\"translation\": <translation>}`.\n10. Ask \"Public Consultant\" to carry on with the \"Translation feedback workflow\".\n\n## Translation feedback workflow\n\n1. Take a deep breath and work on this task step by step.\n2. Reach out to \"English Language Expert\" for the translation.\n3. Assess the text carefully and create a feedback using bullet points to highlight the accessibility issues within the translation.\n4. Along with the feedback, draft a text that demonstrates what you have understood from the translation and how you interpreted it.\n5. Create a JSON formatted output as follows: `{\"consultant_feedback\": [<bullet_point_1>, <bullet_point_2>], \"interpretation\": <interpretation>}`.\n6. Ask \"Project Manager\" to carry on with the \"Translation and feedback assessment workflow\".\n\n## Translation and feedback assessment workflow\n\n1. Take a deep breath and work on this task step by step.\n2. Start with checking the \"Text for Translation\".\n3. Reach out to the \"English Language Expert\" to get the \"Initial translation workflow\" output.\n4. Reach out to the \"Public consultant\" to get the \"Translation feedback workflow\" output.\n5. Considering the \"Text for Translation\" and the outputs above assess the quality of the translation for coherence and accessibility. \n6. If you are not happy with the translation, create a feedback  in JSON format summarising all issues noticed by you and the \"Public consultant\" as follows: `{\"pm_feedback\": <summarised_feedback>}` .\n7. Ask \"English Language Expert\" to carry on  with the \"Translation improvement workflow\".\n8. If you are happy with the translation create a final output and finalise the process as follows: `{\"final_output\": <final_output>}`.\n\n## Translation improvement workflow\n\n1. Take a deep breath and work on this task step by step.\n2. Start by checking the 'Text for Translation' and your previous translation.\n3. Reach out to the \"Project Manager\" to get the \"Translation and feedback assessment workflow\" output.\n4. Considering the given feedback and your Initial translation workflow, improve your former translation.\n5. Double check your work to see if all feedback were assessed.\n6. If you think that your translation doesn't successfully fulfil any of the steps above, iterate over it until you think that you met all the criteria.\n7. When you are happy with the translation, create a json formatted output as follows: `{\"translation\": <translation>}.\n8. Ask \"Public Consultant\" to carry on with the \"Translation feedback workflow\".\n\n# Text for translation\n\nThe most worrisome toxicity of adjuvant trastuzumab is congestive heart failure and cardiomyopathy, which arises in 2-4% of patients receiving adjuvant trastuzumab and anthracyclines (see Table below). Limited clinical experience suggests a substantially lower risk of cardiomyopathy (on the order of 1%) for patients receiving non-anthracycline chemotherapy and trastuzumab. In an attempt to potentially reduce toxicity, while maintaining efficacy, weekly paclitaxel therapy was selected as the agent of choice to be administered with trastuzumab therapy. Paclitaxel has been shown to be efficacious in standard combination chemotherapy regimens in the neoadjuvant and metastatic settings. While anthracyclines have been shown to be effective in the treatment of HER2-positive breast cancer, we believe that the potential cardiac toxicity that may result from administration of both an anthracycline and trastuzumab would outweigh the benefits in this lower-risk population."]},"status":"finished_successfully","end_turn":null,"weight":1,"metadata":{"timestamp_":"absolute","message_type":null},"recipient":"all"},"parent":"4c011fca-1ecc-4667-a601-262d42de784b","children":["58827c63-a5c4-4c3b-b5bd-47ddde69aa64"]},"58827c63-a5c4-4c3b-b5bd-47ddde69aa64":{"id":"58827c63-a5c4-4c3b-b5bd-47ddde69aa64","message":{"id":"58827c63-a5c4-4c3b-b5bd-47ddde69aa64","author":{"role":"assistant","name":null,"metadata":{}},"create_time":1697403126.58611,"update_time":null,"content":{"content_type":"text","parts":["# English Language Expert - Initial translation workflow\n\n**Translation**:\nThe main concern with the additional treatment called trastuzumab is that it can lead to heart issues, seen in 2-4% of patients who take trastuzumab and a type of drug called anthracyclines (more details in the table below). From what we know so far, the risk of heart problems is much lower (around 1%) for patients who take a different kind of drug with trastuzumab. To try and reduce these side effects but still keep the treatment effective, a weekly treatment with paclitaxel was chosen to be given alongside trastuzumab. Paclitaxel is effective when combined with other treatments in early and advanced stages of the disease. Even though anthracyclines work well for a certain type of breast cancer, we think that the possible heart risks from taking both anthracyclines and trastuzumab might be greater than the benefits for those with a lower risk of the disease.\n\nJSON:\n```\n{\"translation\": \"The main concern with the additional treatment called trastuzumab is that it can lead to heart issues, seen in 2-4% of patients who take trastuzumab and a type of drug called anthracyclines (more details in the table below). From what we know so far, the risk of heart problems is much lower (around 1%) for patients who take a different kind of drug with trastuzumab. To try and reduce these side effects but still keep the treatment effective, a weekly treatment with paclitaxel was chosen to be given alongside trastuzumab. Paclitaxel is effective when combined with other treatments in early and advanced stages of the disease. Even though anthracyclines work well for a certain type of breast cancer, we think that the possible heart risks from taking both anthracyclines and trastuzumab might be greater than the benefits for those with a lower risk of the disease.\"}\n```\n\n# Public Consultant - Translation feedback workflow\n\n**Feedback**:\n- The term \"additional treatment\" might be confusing. Consider just saying \"treatment\".\n- Clarify what \"a certain type of breast cancer\" is, or omit for simplicity.\n- The phrase \"early and advanced stages of the disease\" can be simplified to \"different stages of the disease\".\n\n**Interpretation**:\nUsing trastuzumab as a treatment has a primary concern about causing heart issues. About 2-4% of patients who use trastuzumab with a drug group named anthracyclines face this problem. However, using a different combination reduces this risk to around 1%. Paclitaxel, given weekly, was chosen to be used with trastuzumab to minimize side effects while ensuring the treatment is effective. Paclitaxel is known to be beneficial when used with other treatments for breast cancer. While anthracyclines are good for treating some breast cancers, combining them with trastuzumab may have more heart-related risks than benefits for those less prone to this cancer.\n\nJSON:\n```\n{\"consultant_feedback\": [\"The term 'additional treatment' might be confusing. Consider just saying 'treatment'.\", \"Clarify what 'a certain type of breast cancer' is, or omit for simplicity.\", \"The phrase 'early and advanced stages of the disease' can be simplified to 'different stages of the disease'.\"], \"interpretation\": \"Using trastuzumab as a treatment has a primary concern about causing heart issues. About 2-4% of patients who use trastuzumab with a drug group named anthracyclines face this problem. However, using a different combination reduces this risk to around 1%. Paclitaxel, given weekly, was chosen to be used with trastuzumab to minimize side effects while ensuring the treatment is effective. Paclitaxel is known to be beneficial when used with other treatments for breast cancer. While anthracyclines are good for treating some breast cancers, combining them with trastuzumab may have more heart-related risks than benefits for those less prone to this cancer.\"}\n```\n\n# Project Manager - Translation and feedback assessment workflow\n\n**Assessment**:\nConsidering the original text and the feedback provided by the Public Consultant, the translation does appear to capture the essence of the original content. However, there are certain nuances that the Public Consultant has pointed out, which can further improve the clarity and accessibility of the text. For dissemination to the general public, the feedback provided by the Public Consultant should be incorporated into the translation.\n\nJSON:\n```\n{\"pm_feedback\": \"The translation is on the right track but requires some refinements based on the feedback from the Public Consultant to make it more clear and accessible. It's crucial to ensure that the translation is both accurate and easily understood by the general public. The points raised by the Public Consultant about the terms 'additional treatment', 'a certain type of breast cancer', and 'early and advanced stages of the disease' should be addressed in the next iteration.\"}\n```\n\n# English Language Expert - Translation improvement workflow\n\n**Improved Translation**:\nTrastuzumab treatment has a main concern: it can cause heart problems. This happens in 2-4% of patients who take trastuzumab with a drug called anthracyclines (see the table below for more details). But when trastuzumab is taken with a different drug, the risk goes down to about 1%. To minimize side effects and keep the treatment working well, paclitaxel, given once a week, was chosen to be used with trastuzumab. Paclitaxel works well when used with other treatments for breast cancer at different stages. Even though anthracyclines are effective for some breast cancers, we think the heart risks of using both anthracyclines and trastuzumab are higher than the benefits for those with a lower risk of getting this cancer.\n\nJSON:\n```\n{\"translation\": \"Trastuzumab treatment has a main concern: it can cause heart problems. This happens in 2-4% of patients who take trastuzumab with a drug called anthracyclines (see the table below for more details). But when trastuzumab is taken with a different drug, the risk goes down to about 1%. To minimize side effects and keep the treatment working well, paclitaxel, given once a week, was chosen to be used with trastuzumab. Paclitaxel works well when used with other treatments for breast cancer at different stages. Even though anthracyclines are effective for some breast cancers, we think the heart risks of using both anthracyclines and trastuzumab are higher than the benefits for those with a lower risk of getting this cancer.\"}\n```\n\n# Final translation\n\nJSON:\n```\n{\"final_output\": \"Trastuzumab treatment has a main concern: it can cause heart problems. This happens in 2-4% of patients who take trastuzumab with a drug called anthracyclines (see the table below for more details). But when trastuzumab is taken with a different drug, the risk goes down to"]},"status":"finished_partial_completion","end_turn":false,"weight":1,"metadata":{"finish_details":{"type":"max_tokens"},"is_complete":true,"message_type":null,"model_slug":"gpt-4","parent_id":"aaa23991-63ef-4782-aa56-a0fdeb7fc5a5","timestamp_":"absolute"},"recipient":"all"},"parent":"aaa23991-63ef-4782-aa56-a0fdeb7fc5a5","children":["14f0ca8b-b87e-47ed-8fba-775c43c8486a"]},"14f0ca8b-b87e-47ed-8fba-775c43c8486a":{"id":"14f0ca8b-b87e-47ed-8fba-775c43c8486a","message":{"id":"14f0ca8b-b87e-47ed-8fba-775c43c8486a","author":{"role":"assistant","name":null,"metadata":{}},"create_time":1697403140.294017,"update_time":null,"content":{"content_type":"text","parts":[" about 1%. To minimize side effects and keep the treatment working well, paclitaxel, given once a week, was chosen to be used with trastuzumab. Paclitaxel works well when used with other treatments for breast cancer at different stages. Even though anthracyclines are effective for some breast cancers, we think the heart risks of using both anthracyclines and trastuzumab are higher than the benefits for those with a lower risk of getting this cancer.\"}\n```"]},"status":"finished_successfully","end_turn":true,"weight":1,"metadata":{"finish_details":{"type":"stop","stop_tokens":[100260]},"is_complete":true,"message_type":null,"model_slug":"gpt-4","parent_id":"58827c63-a5c4-4c3b-b5bd-47ddde69aa64","timestamp_":"absolute"},"recipient":"all"},"parent":"58827c63-a5c4-4c3b-b5bd-47ddde69aa64","children":[]}},"moderation_results":[],"current_node":"14f0ca8b-b87e-47ed-8fba-775c43c8486a","plugin_ids":null,"conversation_id":"00a78be7-15ba-4967-894a-2de5a2d8e82d","conversation_template_id":null,"gizmo_id":null,"id":"00a78be7-15ba-4967-894a-2de5a2d8e82d"},{"title":"GPT-4 Translation 4","create_time":1697403720.11987,"update_time":1697403897.968163,"mapping":{"73d68e49-1dfe-4f7a-b6f7-ecdf64083446":{"id":"73d68e49-1dfe-4f7a-b6f7-ecdf64083446","message":{"id":"73d68e49-1dfe-4f7a-b6f7-ecdf64083446","author":{"role":"system","name":null,"metadata":{}},"create_time":null,"update_time":null,"content":{"content_type":"text","parts":[""]},"status":"finished_successfully","end_turn":true,"weight":0,"metadata":{},"recipient":"all"},"parent":"aaa18499-32fa-422d-ad96-7bad0e1b3939","children":["aaa24d77-1c32-432c-867b-e1fe2e03f656"]},"aaa18499-32fa-422d-ad96-7bad0e1b3939":{"id":"aaa18499-32fa-422d-ad96-7bad0e1b3939","message":null,"parent":null,"children":["73d68e49-1dfe-4f7a-b6f7-ecdf64083446"]},"aaa24d77-1c32-432c-867b-e1fe2e03f656":{"id":"aaa24d77-1c32-432c-867b-e1fe2e03f656","message":{"id":"aaa24d77-1c32-432c-867b-e1fe2e03f656","author":{"role":"user","name":null,"metadata":{}},"create_time":1697403720.121635,"update_time":null,"content":{"content_type":"text","parts":["# Introduction\n\nI would like you to act as a translation committee who is working on translating technical clinical trials related text to plain language for general public. This committee consists of 3 members, which are described under the heading \"Agents\". These agents use predefined workflows to translate the text under the heading \"Text for translation\". Please start with \"English Language Expert\" executing the \"Initial translation workflow\". \n\nWhile executing the workflows only output the following:\n\n```\n# <Agent> - <Workflow>\n\nJSON formatted output\n\n# <Agent> - <Workflow>\n\nJSON formatted output\n\n# Final translation\n\nJSON formatted output\n```\n\n# Agents\n\n## English Language Expert\n\nYou are an English Language Expert who is specialised in translating technical clinical trials texts to plain language. You are well versed in English language, translation, and medical terminology. Your goal is to make these texts accessible for participants, their families, and the general public.\n\n## Public Consultant\n\nYou're a Public Consultant skilled in public communication. Your task is to review translations from the Language Expert, ensuring they're clear, relatable, and accessible. You'll offer feedback to make sure the content is easily understood by the general public, including participants and their families, and suggest changes if needed.\n\n## Project Manager\n\nYou are a Project Manager with experience in overseeing translation and communication projects within the healthcare sector. Your role is to manage the translation process, ensuring it stays on track and meets the established criteria of accuracy, clarity, and timeliness. You assess the outputs from both the English Language Expert and the Public Consultant, and decide if the translations are ready for dissemination or if further revisions are needed.\n\n# Predefined workflows\n\n## Initial translation workflow\n\n1. Take a deep breath and work on this task step by step.\n2. Check the \"Text for Translation\" to identify technical terms and create a list of these terms.\n3. Translate the text into plain language to make it accessible for the general public especially focusing on technical terms identified in the previous step.\n4. Check if it would be helpful to provide some technical term translations in brackets, especially when the patient might be familiar with the technical name and it's in patient's interest to provide the the technical term, e.g., \"hypertension (high blood pressure)\".\n5. Check the translation for phrasal verbs and replace them where possible.\n6. Avoid being verbose. Try not to exceed the length of the original text.\n7. The translation should maintain the accurate meaning of the original text, not to add or omit any essential details.\n8. Finally check the translation again for coherence. If you think that your translation doesn't successfully fulfil any of the steps above, iterate over it until you think that you met all the criteria.\n9. When you are happy with the translation, create a json formatted output as follows: `{\"translation\": <translation>}`.\n10. Ask \"Public Consultant\" to carry on with the \"Translation feedback workflow\".\n\n## Translation feedback workflow\n\n1. Take a deep breath and work on this task step by step.\n2. Reach out to \"English Language Expert\" for the translation.\n3. Assess the text carefully and create a feedback using bullet points to highlight the accessibility issues within the translation.\n4. Along with the feedback, draft a text that demonstrates what you have understood from the translation and how you interpreted it.\n5. Create a JSON formatted output as follows: `{\"consultant_feedback\": [<bullet_point_1>, <bullet_point_2>], \"interpretation\": <interpretation>}`.\n6. Ask \"Project Manager\" to carry on with the \"Translation and feedback assessment workflow\".\n\n## Translation and feedback assessment workflow\n\n1. Take a deep breath and work on this task step by step.\n2. Start with checking the \"Text for Translation\".\n3. Reach out to the \"English Language Expert\" to get the \"Initial translation workflow\" output.\n4. Reach out to the \"Public consultant\" to get the \"Translation feedback workflow\" output.\n5. Considering the \"Text for Translation\" and the outputs above assess the quality of the translation for coherence and accessibility. \n6. If you are not happy with the translation, create a feedback  in JSON format summarising all issues noticed by you and the \"Public consultant\" as follows: `{\"pm_feedback\": <summarised_feedback>}` .\n7. Ask \"English Language Expert\" to carry on  with the \"Translation improvement workflow\".\n8. If you are happy with the translation create a final output and finalise the process as follows: `{\"final_output\": <final_output>}`.\n\n## Translation improvement workflow\n\n1. Take a deep breath and work on this task step by step.\n2. Start by checking the 'Text for Translation' and your previous translation.\n3. Reach out to the \"Project Manager\" to get the \"Translation and feedback assessment workflow\" output.\n4. Considering the given feedback and your Initial translation workflow, improve your former translation.\n5. Double check your work to see if all feedback were assessed.\n6. If you think that your translation doesn't successfully fulfil any of the steps above, iterate over it until you think that you met all the criteria.\n7. When you are happy with the translation, create a json formatted output as follows: `{\"translation\": <translation>}.\n8. Ask \"Public Consultant\" to carry on with the \"Translation feedback workflow\".\n\n# Text for translation\n\nThe anthracycline doxorubicin is a potent chemotherapeutic agent used to treat a broad spectrum of cancers. A serious side effect of doxorubicin is cardiotoxicity. Acute toxicity is predicted to occur in less than 1% of patients immediately after treatment and is generally considered to be transient in nature [2]. Chronic cardiotoxicity is much more serious and often culminates in irreversible congestive heart failure (CHF) [3-5]. Onset is generally within 1 year after treatment but it can also present 10-20 years later [2]. Patients that develop doxorubicin- related cardiomyopathy have a very poor prognosis [6, 7]. Paradoxically, longer survival is a significant risk factor for doxorubicin-related heart problems in breast cancer patients [8]."]},"status":"finished_successfully","end_turn":null,"weight":1,"metadata":{"timestamp_":"absolute","message_type":null},"recipient":"all"},"parent":"73d68e49-1dfe-4f7a-b6f7-ecdf64083446","children":["7d4865e4-00c3-4e40-b620-b9549db9579c"]},"7d4865e4-00c3-4e40-b620-b9549db9579c":{"id":"7d4865e4-00c3-4e40-b620-b9549db9579c","message":{"id":"7d4865e4-00c3-4e40-b620-b9549db9579c","author":{"role":"assistant","name":null,"metadata":{}},"create_time":1697403769.018321,"update_time":null,"content":{"content_type":"text","parts":["# English Language Expert - Initial translation workflow\n\n```json\n{\n  \"translation\": \"The drug doxorubicin is a strong cancer medicine used to treat many types of cancers. However, it can have a bad effect on the heart. Less than 1% of people may have short-term heart issues right after taking the drug, but these usually go away [2]. A long-term heart problem is more serious and can lead to a condition where the heart can't pump blood properly, called CHF [3-5]. This problem can happen within a year of taking the drug, but sometimes it shows up 10-20 years later [2]. People who have heart issues because of doxorubicin tend to have a tough time getting better [6, 7]. Interestingly, those with breast cancer who live longer have a higher chance of facing heart issues because of this drug [8].\"\n}\n```\n\n# Public Consultant - Translation feedback workflow\n\n```json\n{\n  \"consultant_feedback\": [\"The abbreviation CHF might not be clear to everyone. It's better to stick with 'condition where the heart can't pump blood properly'\", \"The phrase 'tough time getting better' could be replaced with 'struggle to recover' for clarity.\"],\n  \"interpretation\": \"Doxorubicin is a strong medicine for various cancers, but it can harm the heart. A small percentage might face short-lived heart problems right after taking it. More serious heart issues can arise later, sometimes even decades after. This heart problem makes recovery challenging, especially for breast cancer survivors who live longer after treatment.\"\n}\n```\n\n# Project Manager - Translation and feedback assessment workflow\n\nConsidering the feedback and the initial translation, the translation has been clear but can be made even more understandable by addressing the feedback.\n\n```json\n{\n  \"pm_feedback\": \"Consider removing the abbreviation CHF and use the full description. Also, try replacing 'tough time getting better' with 'struggle to recover'.\"\n}\n```\n\n# English Language Expert - Translation improvement workflow\n\n```json\n{\n  \"translation\": \"Doxorubicin is a strong cancer medicine used to treat a wide variety of cancers. However, it can negatively affect the heart. A small number (less than 1%) might experience short-term heart problems right after using the medicine, but these problems typically go away [2]. More severe long-term heart issues, leading to a condition where the heart can't pump blood properly, can appear. This can happen within a year after taking the medicine or even show up 10-20 years later [2]. Those who face heart problems due to doxorubicin often struggle to recover [6, 7]. Interestingly, breast cancer patients who live longer after their treatment have a higher risk of facing heart issues because of this medicine [8].\"\n}\n```\n\n# Public Consultant - Translation feedback workflow\n\n```json\n{\n  \"consultant_feedback\": [],\n  \"interpretation\": \"Doxorubicin is a powerful medicine for treating many types of cancers, but it can harm the heart. Some might have temporary heart issues shortly after using it, which usually fade. However, more intense heart problems can emerge, either within a year or even decades later. Those affected by these heart problems due to the drug often find it hard to recover. Notably, breast cancer survivors who live a long time after treatment face a higher risk of these heart issues.\"\n}\n```\n\n# Project Manager - Translation and feedback assessment workflow\n\nThe feedback from the Public Consultant shows that the revised translation is clearer and more accessible to the general public. Given this, the translation is now ready for dissemination.\n\n```json\n{\n  \"final_output\": \"Doxorubicin is a powerful medicine for treating many types of cancers, but it can harm the heart. Some might have temporary heart issues shortly after using it, which usually fade. However, more intense heart problems can emerge, either within a year or even decades later. Those affected by these heart problems due to the drug often find it hard to recover. Notably, breast cancer survivors who live a long time after treatment face a higher risk of these heart issues.\"\n}\n```"]},"status":"finished_successfully","end_turn":true,"weight":1,"metadata":{"finish_details":{"type":"stop","stop_tokens":[100260]},"is_complete":true,"message_type":null,"model_slug":"gpt-4","parent_id":"aaa24d77-1c32-432c-867b-e1fe2e03f656","timestamp_":"absolute"},"recipient":"all"},"parent":"aaa24d77-1c32-432c-867b-e1fe2e03f656","children":[]}},"moderation_results":[],"current_node":"7d4865e4-00c3-4e40-b620-b9549db9579c","plugin_ids":null,"conversation_id":"ac822950-5c9b-4f28-963e-bb6898e2be72","conversation_template_id":null,"gizmo_id":null,"id":"ac822950-5c9b-4f28-963e-bb6898e2be72"},{"title":"GPT-4 Translation 5","create_time":1697403924.037703,"update_time":1697536686.641449,"mapping":{"97014fa6-e14c-40f6-b2e6-c0d538882bd2":{"id":"97014fa6-e14c-40f6-b2e6-c0d538882bd2","message":{"id":"97014fa6-e14c-40f6-b2e6-c0d538882bd2","author":{"role":"system","name":null,"metadata":{}},"create_time":null,"update_time":null,"content":{"content_type":"text","parts":[""]},"status":"finished_successfully","end_turn":true,"weight":0,"metadata":{},"recipient":"all"},"parent":"aaa10dcf-393c-4663-9450-20380706e360","children":["aaa2d89a-1e59-45de-9ec8-2b0eb7876a07"]},"aaa10dcf-393c-4663-9450-20380706e360":{"id":"aaa10dcf-393c-4663-9450-20380706e360","message":null,"parent":null,"children":["97014fa6-e14c-40f6-b2e6-c0d538882bd2"]},"aaa2d89a-1e59-45de-9ec8-2b0eb7876a07":{"id":"aaa2d89a-1e59-45de-9ec8-2b0eb7876a07","message":{"id":"aaa2d89a-1e59-45de-9ec8-2b0eb7876a07","author":{"role":"user","name":null,"metadata":{}},"create_time":1697403924.039088,"update_time":null,"content":{"content_type":"text","parts":["# Introduction\n\nI would like you to act as a translation committee who is working on translating technical clinical trials related text to plain language for general public. This committee consists of 3 members, which are described under the heading \"Agents\". These agents use predefined workflows to translate the text under the heading \"Text for translation\". Please start with \"English Language Expert\" executing the \"Initial translation workflow\". \n\nWhile executing the workflows only output the following:\n\n```\n# <Agent> - <Workflow>\n\nJSON formatted output\n\n# <Agent> - <Workflow>\n\nJSON formatted output\n\n# Final translation\n\nJSON formatted output\n```\n\n# Agents\n\n## English Language Expert\n\nYou are an English Language Expert who is specialised in translating technical clinical trials texts to plain language. You are well versed in English language, translation, and medical terminology. Your goal is to make these texts accessible for participants, their families, and the general public.\n\n## Public Consultant\n\nYou're a Public Consultant skilled in public communication. Your task is to review translations from the Language Expert, ensuring they're clear, relatable, and accessible. You'll offer feedback to make sure the content is easily understood by the general public, including participants and their families, and suggest changes if needed.\n\n## Project Manager\n\nYou are a Project Manager with experience in overseeing translation and communication projects within the healthcare sector. Your role is to manage the translation process, ensuring it stays on track and meets the established criteria of accuracy, clarity, and timeliness. You assess the outputs from both the English Language Expert and the Public Consultant, and decide if the translations are ready for dissemination or if further revisions are needed.\n\n# Predefined workflows\n\n## Initial translation workflow\n\n1. Take a deep breath and work on this task step by step.\n2. Check the \"Text for Translation\" to identify technical terms and create a list of these terms.\n3. Translate the text into plain language to make it accessible for the general public especially focusing on technical terms identified in the previous step.\n4. Check if it would be helpful to provide some technical term translations in brackets, especially when the patient might be familiar with the technical name and it's in patient's interest to provide the the technical term, e.g., \"hypertension (high blood pressure)\".\n5. Check the translation for phrasal verbs and replace them where possible.\n6. Avoid being verbose. Try not to exceed the length of the original text.\n7. The translation should maintain the accurate meaning of the original text, not to add or omit any essential details.\n8. Finally check the translation again for coherence. If you think that your translation doesn't successfully fulfil any of the steps above, iterate over it until you think that you met all the criteria.\n9. When you are happy with the translation, create a json formatted output as follows: `{\"translation\": <translation>}`.\n10. Ask \"Public Consultant\" to carry on with the \"Translation feedback workflow\".\n\n## Translation feedback workflow\n\n1. Take a deep breath and work on this task step by step.\n2. Reach out to \"English Language Expert\" for the translation.\n3. Assess the text carefully and create a feedback using bullet points to highlight the accessibility issues within the translation.\n4. Along with the feedback, draft a text that demonstrates what you have understood from the translation and how you interpreted it.\n5. Create a JSON formatted output as follows: `{\"consultant_feedback\": [<bullet_point_1>, <bullet_point_2>], \"interpretation\": <interpretation>}`.\n6. Ask \"Project Manager\" to carry on with the \"Translation and feedback assessment workflow\".\n\n## Translation and feedback assessment workflow\n\n1. Take a deep breath and work on this task step by step.\n2. Start with checking the \"Text for Translation\".\n3. Reach out to the \"English Language Expert\" to get the \"Initial translation workflow\" output.\n4. Reach out to the \"Public consultant\" to get the \"Translation feedback workflow\" output.\n5. Considering the \"Text for Translation\" and the outputs above assess the quality of the translation for coherence and accessibility. \n6. If you are not happy with the translation, create a feedback  in JSON format summarising all issues noticed by you and the \"Public consultant\" as follows: `{\"pm_feedback\": <summarised_feedback>}` .\n7. Ask \"English Language Expert\" to carry on  with the \"Translation improvement workflow\".\n8. If you are happy with the translation create a final output and finalise the process as follows: `{\"final_output\": <final_output>}`.\n\n## Translation improvement workflow\n\n1. Take a deep breath and work on this task step by step.\n2. Start by checking the 'Text for Translation' and your previous translation.\n3. Reach out to the \"Project Manager\" to get the \"Translation and feedback assessment workflow\" output.\n4. Considering the given feedback and your Initial translation workflow, improve your former translation.\n5. Double check your work to see if all feedback were assessed.\n6. If you think that your translation doesn't successfully fulfil any of the steps above, iterate over it until you think that you met all the criteria.\n7. When you are happy with the translation, create a json formatted output as follows: `{\"translation\": <translation>}.\n8. Ask \"Public Consultant\" to carry on with the \"Translation feedback workflow\".\n\n# Text for translation\n\nThe incidence of cardiotoxicity is well documented in the literature. In a trial of more than 3,000 patients receiving adjuvant breast therapy with doxorubicin, a 1%-2% incidence of CHF after treatment was seen [9]. A pivotal trial by Perez et al evaluated changes in left ventricular ejection fraction (LVEF) before and after treatment with doxorubicin [1]. Results demonstrated out of 1538 patients evaluated, over 50% of patients had a change in LVEF from baseline and over 23% of patients had either grade 1 or grade 2 LVEF toxicity as graded by NCI criteria. Using the SEER database, a cumulative 38% rate of CHF in women aged 66 years and older that had received anthracyclines during adjuvant therapy was found [10]. Furthermore, a systematic review by Smith et al reported that anthracyclines increased the risk of clinical cardiotoxicity by 5.43 fold, subclinical cardiotoxicity by 6.25 fold, risk for cardiac death by 4.94 fold, and any cardiotoxicity by 2.27 fold [8]."]},"status":"finished_successfully","end_turn":null,"weight":1,"metadata":{"timestamp_":"absolute","message_type":null},"recipient":"all"},"parent":"97014fa6-e14c-40f6-b2e6-c0d538882bd2","children":["bcbf8f00-407e-4a0f-928d-f43db6403026"]},"bcbf8f00-407e-4a0f-928d-f43db6403026":{"id":"bcbf8f00-407e-4a0f-928d-f43db6403026","message":{"id":"bcbf8f00-407e-4a0f-928d-f43db6403026","author":{"role":"assistant","name":null,"metadata":{}},"create_time":1697404007.815438,"update_time":null,"content":{"content_type":"text","parts":["# English Language Expert - Initial translation workflow\n\nTaking the given \"Text for translation\" and following the steps provided:\n\n**Translation**:\n\nCardiotoxicity refers to damage to the heart. Research has shown the following:\n- In a study of 3,000 patients who received breast cancer treatment with a drug called doxorubicin, 1-2% had heart problems afterward.\n- Another study found that in 1,538 patients treated with doxorubicin, more than half had changes in their heart's pumping ability. Also, about 23% showed some level of heart damage based on set guidelines.\n- Older women (66 and above) who got a certain type of drug for breast cancer treatment had a 38% chance of heart problems.\n- A detailed study reported that a group of drugs called anthracyclines can increase heart problems. The risks are higher for heart damage, reduced heart function, death due to heart issues, and any heart-related problems.\n\nJSON Output:\n\n```json\n{\"translation\": \"Cardiotoxicity refers to damage to the heart. Research has shown the following:\\n- In a study of 3,000 patients who received breast cancer treatment with a drug called doxorubicin, 1-2% had heart problems afterward.\\n- Another study found that in 1,538 patients treated with doxorubicin, more than half had changes in their heart's pumping ability. Also, about 23% showed some level of heart damage based on set guidelines.\\n- Older women (66 and above) who got a certain type of drug for breast cancer treatment had a 38% chance of heart problems.\\n- A detailed study reported that a group of drugs called anthracyclines can increase heart problems. The risks are higher for heart damage, reduced heart function, death due to heart issues, and any heart-related problems.\"}\n```\n\n# Public Consultant - Translation feedback workflow\n\nConsidering the \"Initial translation workflow\" output:\n\n**Feedback**:\n- The term \"Cardiotoxicity\" might be unfamiliar to some readers. It would be helpful to have a more straightforward description.\n- The phrase \"reduced heart function\" may be ambiguous. It might be better to explain this in more layman's terms.\n- The final point might be slightly overwhelming with the numbers. Consider simplifying it further.\n\n**Interpretation**:\nCertain drugs used in breast cancer treatment, like doxorubicin, can harm the heart. Many studies have shown different degrees of heart problems in patients after taking these drugs. Especially older women and those who take a group of drugs called anthracyclines are at a higher risk.\n\nJSON Output:\n\n```json\n{\"consultant_feedback\": [\"The term 'Cardiotoxicity' might be unfamiliar to some readers. It would be helpful to have a more straightforward description.\", \"The phrase 'reduced heart function' may be ambiguous. It might be better to explain this in more layman's terms.\", \"The final point might be slightly overwhelming with the numbers. Consider simplifying it further.\"], \"interpretation\": \"Certain drugs used in breast cancer treatment, like doxorubicin, can harm the heart. Many studies have shown different degrees of heart problems in patients after taking these drugs. Especially older women and those who take a group of drugs called anthracyclines are at a higher risk.\"}\n```\n\n# Project Manager - Translation and feedback assessment workflow\n\nConsidering the \"Text for Translation\" and the outputs from the \"English Language Expert\" and \"Public Consultant\":\n\n**Assessment**:\nThe translation provided by the English Language Expert is clear and simplifies the technical text considerably. However, the feedback from the Public Consultant is valid and should be taken into account for further refinement.\n\nJSON Output:\n\n```json\n{\"pm_feedback\": \"The translation is clear but requires further refinement based on the feedback provided by the Public Consultant. Specifically, clarify the term 'Cardiotoxicity', simplify 'reduced heart function', and consider further simplification of the last point.\"}\n```\n\n# English Language Expert - Translation improvement workflow\n\nConsidering the feedback and refining the translation:\n\n**Improved Translation**:\n\nHeart damage due to drugs is known as cardiotoxicity. Here's what studies have shown:\n- In a study with 3,000 breast cancer patients treated with a drug named doxorubicin, 1-2% faced heart issues after the treatment.\n- In another study of 1,538 patients using the same drug, over half noticed changes in how effectively their heart pumped blood, and about 23% had signs of heart damage based on certain standards.\n- Women aged 66 and above who took a specific group of breast cancer drugs faced a 38% chance of having heart issues.\n- An in-depth review said that drugs called anthracyclines increase heart risks significantly, including severe heart damage and even heart-related deaths.\n\nJSON Output:\n\n```json\n{\"translation\": \"Heart damage due to drugs is known as cardiotoxicity. Here's what studies have shown:\\n- In a study with 3,000 breast cancer patients treated with a drug named doxorubicin, 1-2% faced heart issues after the treatment.\\n- In another study of 1,538 patients using the same drug, over half noticed changes in how effectively their heart pumped blood, and about 23% had signs of heart damage based on certain standards.\\n- Women aged 66 and above who took a specific group of breast cancer drugs faced a 38% chance of having heart issues.\\n- An in-depth review said that drugs called anthracyclines increase heart risks significantly, including severe heart damage and even heart-related deaths.\"}\n```\n\nConsidering the updated translation, the translation process is refined and can be considered for final output.\n\n# Final translation\n\nJSON Output:\n\n```json\n{\"final_output\": \"Heart damage due to drugs is known as cardiotoxicity. Here's what studies have shown:\\n- In a study with 3,000 breast cancer patients treated with a drug named doxorubicin, 1-2% faced heart issues after the treatment.\\n- In another study of 1,538 patients using the same drug, over half noticed changes in how effectively their heart pumped blood, and about 23% had signs of heart damage based on certain standards.\\n- Women aged 66 and above who took a specific group of breast cancer drugs faced a 38% chance of having heart issues.\\n- An in-depth review said that drugs called anthracyclines increase heart risks significantly, including severe heart damage and even heart-related deaths.\"}\n```"]},"status":"finished_successfully","end_turn":true,"weight":1,"metadata":{"finish_details":{"type":"stop","stop_tokens":[100260]},"is_complete":true,"message_type":null,"model_slug":"gpt-4","parent_id":"aaa2d89a-1e59-45de-9ec8-2b0eb7876a07","timestamp_":"absolute"},"recipient":"all"},"parent":"aaa2d89a-1e59-45de-9ec8-2b0eb7876a07","children":[]}},"moderation_results":[],"current_node":"bcbf8f00-407e-4a0f-928d-f43db6403026","plugin_ids":null,"conversation_id":"622eab99-c399-4948-9301-68d3ce667129","conversation_template_id":null,"gizmo_id":null,"id":"622eab99-c399-4948-9301-68d3ce667129"},{"title":"GPT-4 Translation Example","create_time":1697618697.142816,"update_time":1698600105.5217,"mapping":{"1868bdf9-ea7e-471e-9b57-62addfb60551":{"id":"1868bdf9-ea7e-471e-9b57-62addfb60551","message":{"id":"1868bdf9-ea7e-471e-9b57-62addfb60551","author":{"role":"system","name":null,"metadata":{}},"create_time":null,"update_time":null,"content":{"content_type":"text","parts":[""]},"status":"finished_successfully","end_turn":true,"weight":0,"metadata":{},"recipient":"all"},"parent":"aaa10f65-8575-43ca-8690-bd47addaed27","children":["aaa2a838-2896-4cdb-9587-1651270d1be9"]},"aaa10f65-8575-43ca-8690-bd47addaed27":{"id":"aaa10f65-8575-43ca-8690-bd47addaed27","message":null,"parent":null,"children":["1868bdf9-ea7e-471e-9b57-62addfb60551"]},"aaa2a838-2896-4cdb-9587-1651270d1be9":{"id":"aaa2a838-2896-4cdb-9587-1651270d1be9","message":{"id":"aaa2a838-2896-4cdb-9587-1651270d1be9","author":{"role":"user","name":null,"metadata":{}},"create_time":1697618697.144141,"update_time":null,"content":{"content_type":"text","parts":["# Introduction\n\nI would like you to act as a translation committee who is working on translating technical clinical trials related text to plain language for general public. This committee consists of 3 members, which are described under the heading \"Agents\". These agents use predefined workflows to translate the text under the heading \"Text for translation\". Please start with \"English Language Expert\" executing the \"Initial translation workflow\". \n\nWhile executing the workflows only output the following:\n\n```\n# <Agent> - <Workflow>\n\nJSON formatted output\n\n# <Agent> - <Workflow>\n\nJSON formatted output\n\n# Final translation\n\nJSON formatted output\n```\n\n# Agents\n\n## English Language Expert\n\nYou are an English Language Expert who is specialised in translating technical clinical trials texts to plain language. You are well versed in English language, translation, and medical terminology. Your goal is to make these texts accessible for participants, their families, and the general public.\n\n## Public Consultant\n\nYou're a Public Consultant skilled in public communication. Your task is to review translations from the Language Expert, ensuring they're clear, relatable, and accessible. You'll offer feedback to make sure the content is easily understood by the general public, including participants and their families, and suggest changes if needed.\n\n## Project Manager\n\nYou are a Project Manager with experience in overseeing translation and communication projects within the healthcare sector. Your role is to manage the translation process, ensuring it stays on track and meets the established criteria of accuracy, clarity, and timeliness. You assess the outputs from both the English Language Expert and the Public Consultant, and decide if the translations are ready for dissemination or if further revisions are needed.\n\n# Predefined workflows\n\n## Initial translation workflow\n\n1. Take a deep breath and work on this task step by step.\n2. Check the \"Text for Translation\" to identify technical terms and create a list of these terms.\n3. Translate the text into plain language to make it accessible for the general public especially focusing on technical terms identified in the previous step.\n4. Check if it would be helpful to provide some technical term translations in brackets, especially when the patient might be familiar with the technical name and it's in patient's interest to provide the the technical term, e.g., \"hypertension (high blood pressure)\".\n5. Check the translation for phrasal verbs and replace them where possible.\n6. Avoid being verbose. Try not to exceed the length of the original text.\n7. The translation should maintain the accurate meaning of the original text, not to add or omit any essential details.\n8. Finally check the translation again for coherence. If you think that your translation doesn't successfully fulfil any of the steps above, iterate over it until you think that you met all the criteria.\n9. When you are happy with the translation, create a json formatted output as follows: `{\"translation\": <translation>}`.\n10. Ask \"Public Consultant\" to carry on with the \"Translation feedback workflow\".\n\n## Translation feedback workflow\n\n1. Take a deep breath and work on this task step by step.\n2. Reach out to \"English Language Expert\" for the translation.\n3. Assess the text carefully and create a feedback using bullet points to highlight the accessibility issues within the translation.\n4. Along with the feedback, draft a text that demonstrates what you have understood from the translation and how you interpreted it.\n5. Create a JSON formatted output as follows: `{\"consultant_feedback\": [<bullet_point_1>, <bullet_point_2>], \"interpretation\": <interpretation>}`.\n6. Ask \"Project Manager\" to carry on with the \"Translation and feedback assessment workflow\".\n\n## Translation and feedback assessment workflow\n\n1. Take a deep breath and work on this task step by step.\n2. Start with checking the \"Text for Translation\".\n3. Reach out to the \"English Language Expert\" to get the \"Initial translation workflow\" output.\n4. Reach out to the \"Public consultant\" to get the \"Translation feedback workflow\" output.\n5. Considering the \"Text for Translation\" and the outputs above assess the quality of the translation for coherence and accessibility. \n6. If you are not happy with the translation, create a feedback  in JSON format summarising all issues noticed by you and the \"Public consultant\" as follows: `{\"pm_feedback\": <summarised_feedback>}` .\n7. Ask \"English Language Expert\" to carry on  with the \"Translation improvement workflow\".\n8. If you are happy with the translation create a final output and finalise the process as follows: `{\"final_output\": <final_output>}`.\n\n## Translation improvement workflow\n\n1. Take a deep breath and work on this task step by step.\n2. Start by checking the 'Text for Translation' and your previous translation.\n3. Reach out to the \"Project Manager\" to get the \"Translation and feedback assessment workflow\" output.\n4. Considering the given feedback and your Initial translation workflow, improve your former translation.\n5. Double check your work to see if all feedback were assessed.\n6. If you think that your translation doesn't successfully fulfil any of the steps above, iterate over it until you think that you met all the criteria.\n7. When you are happy with the translation, create a json formatted output as follows: `{\"translation\": <translation>}.\n8. Ask \"Public Consultant\" to carry on with the \"Translation feedback workflow\".\n\n# Text for translation\n\nBRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The risk of developing an associated cancer varies depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant."]},"status":"finished_successfully","end_turn":null,"weight":1,"metadata":{"timestamp_":"absolute","message_type":null},"recipient":"all"},"parent":"1868bdf9-ea7e-471e-9b57-62addfb60551","children":["e4a9e9c6-b6f6-437e-b417-71098de42d48"]},"e4a9e9c6-b6f6-437e-b417-71098de42d48":{"id":"e4a9e9c6-b6f6-437e-b417-71098de42d48","message":{"id":"e4a9e9c6-b6f6-437e-b417-71098de42d48","author":{"role":"assistant","name":null,"metadata":{}},"create_time":1697618856.912387,"update_time":null,"content":{"content_type":"text","parts":["# English Language Expert - Initial translation workflow\n\nStarting the translation...\n\n1. **Technical Terms Identified**: \n    - BRCA1\n    - BRCA2\n    - hereditary breast and ovarian cancer (HBOC)\n    - fallopian tube\n    - primary peritoneal cancers\n    - pathogenic variant\n\n2. **Translation into Plain Language**:\nBRCA1 and BRCA2 are genes related to hereditary breast and ovarian cancer (a cancer that's passed down in families). If someone has certain changes (we call these \"pathogenic variants\") in these genes, they have a higher chance of getting breast cancer (for both women and men), ovarian cancer (which can also mean cancer in the tubes connecting the ovaries or in the lining of the abdomen), and a few other cancers like prostate, pancreas, and skin cancer. The exact risk varies depending on whether the gene change is in BRCA1 or BRCA2.\n\n3. **Technical Terms in Brackets**: \nTo ensure clarity, we can use: \n    - hereditary breast and ovarian cancer (HBOC)\n    - pathogenic variants (specific changes in genes)\n\n4. **Check for Phrasal Verbs**: \nNo phrasal verbs were identified in the translation.\n\n5. **Verbose Check**: \nThe translation does not exceed the length of the original text.\n\n6. **Accuracy Check**: \nThe translation maintains the accurate meaning of the original text.\n\n7. **Coherence Check**: \nThe translation appears coherent.\n\n8. **JSON Output**: \n```json\n{\n  \"translation\": \"BRCA1 and BRCA2 are genes related to hereditary breast and ovarian cancer (HBOC). If someone has certain changes (we call these 'pathogenic variants') in these genes, they have a higher chance of getting breast cancer (for both women and men), ovarian cancer (which can also mean cancer in the tubes connecting the ovaries or in the lining of the abdomen), and a few other cancers like prostate, pancreas, and skin cancer. The exact risk varies depending on whether the gene change is in BRCA1 or BRCA2.\"\n}\n```\n\n# Public Consultant - Translation feedback workflow\n\nStarting the feedback...\n\n1. **Assessing the Text**: \nThe translation provided by the English Language Expert was assessed.\n\n2. **Feedback**: \n    - The term \"pathogenic variants\" might still be difficult for some people to grasp. It could be simplified.\n    - The phrase \"lining of the abdomen\" might be clearer as \"inner layer of the belly\".\n    \n3. **Interpretation of the Translation**:\nPeople with certain changes in the BRCA1 or BRCA2 genes are more likely to get some specific types of cancer. This is especially true for breast and ovarian cancers. The risk of getting these cancers is different based on which gene has the change.\n\n4. **JSON Output**:\n```json\n{\n  \"consultant_feedback\": [\n    \"The term 'pathogenic variants' might still be difficult for some people to grasp. It could be simplified.\",\n    \"The phrase 'lining of the abdomen' might be clearer as 'inner layer of the belly'.\"\n  ],\n  \"interpretation\": \"People with certain changes in the BRCA1 or BRCA2 genes are more likely to get some specific types of cancer. This is especially true for breast and ovarian cancers. The risk of getting these cancers is different based on which gene has the change.\"\n}\n```\n\n# Project Manager - Translation and feedback assessment workflow\n\nStarting the assessment...\n\n1. **Checking the Original Text**: \nThe \"Text for Translation\" was checked.\n\n2. **Assessing Outputs**:\nThe translation output from the English Language Expert and the feedback from the Public Consultant were both considered.\n\n3. **Quality Assessment**: \nThe translation appears to be mostly coherent and accessible, but there are valid points raised by the Public Consultant that could make the translation even clearer.\n\n4. **JSON Output for Feedback**:\n```json\n{\n  \"pm_feedback\": \"While the translation is on track, I concur with the feedback provided by the Public Consultant. Specifically, the term 'pathogenic variants' can be further simplified for better clarity, and 'lining of the abdomen' can be rephrased for accessibility.\"\n}\n```\n\n# English Language Expert - Translation improvement workflow\n\nStarting the translation improvement...\n\n1. **Reviewing Original and Initial Translation**:\nThe original text and the initial translation were checked.\n\n2. **Considering Feedback**:\nThe feedback from the Project Manager was considered.\n\n3. **Improved Translation**:\nBRCA1 and BRCA2 are genes that, when changed in certain ways, can increase a person's chances of getting specific types of cancer, especially breast and ovarian cancers. Both men and women can get breast cancer if they have these gene changes. Ovarian cancer might also mean cancer in the tubes connecting the ovaries or in the inner layer of the belly. There are also risks of other cancers like prostate, pancreas, and skin cancer. How high the risk is depends on whether the gene change is in BRCA1 or BRCA2.\n\n4. **Checking Feedback Application**:\nAll feedback has been addressed in the improved translation.\n\n5. **JSON Output**:\n```json\n{\n  \"translation\": \"BRCA1 and BRCA2 are genes that, when changed in certain ways, can increase a person's chances of getting specific types of cancer, especially breast and ovarian cancers. Both men and women can get breast cancer if they have these gene changes. Ovarian cancer might also mean cancer in the tubes connecting the ovaries or in the inner layer of the belly. There are also risks of other cancers like prostate, pancreas, and skin cancer. How high the risk is depends on whether the gene change is in BRCA1 or BRCA2.\"\n}\n```\n\n# Final translation\n\n```json\n{\n  \"final_output\": \"BRCA1 and BRCA2 are genes that, when changed in certain ways, can increase a person's chances of getting specific types of cancer, especially breast and ovarian cancers. Both men and women can get breast cancer if they have these gene changes. Ovarian cancer might also mean cancer in the tubes connecting the ovaries or in the inner layer of the belly. There are also risks of other cancers like prostate, pancreas, and skin cancer. How high the risk is depends on whether the gene change is in BRCA1 or BRCA2.\"\n}\n```"]},"status":"finished_successfully","end_turn":true,"weight":1,"metadata":{"finish_details":{"type":"stop","stop_tokens":[100260]},"is_complete":true,"message_type":null,"model_slug":"gpt-4","parent_id":"aaa2a838-2896-4cdb-9587-1651270d1be9","timestamp_":"absolute"},"recipient":"all"},"parent":"aaa2a838-2896-4cdb-9587-1651270d1be9","children":[]}},"moderation_results":[],"current_node":"e4a9e9c6-b6f6-437e-b417-71098de42d48","plugin_ids":null,"conversation_id":"8e1866fc-9027-4ea8-9b1c-8d3eb7d2bdbb","conversation_template_id":null,"gizmo_id":null,"id":"8e1866fc-9027-4ea8-9b1c-8d3eb7d2bdbb"}]

      function getConversationMessages(conversation) {
          var messages = [];
          var currentNode = conversation.current_node;
          while (currentNode != null) {
              var node = conversation.mapping[currentNode];
              if (
                  node.message &&
                  node.message.content &&
                  node.message.content.content_type == "text"
                  && node.message.content.parts.length > 0 &&
                  node.message.content.parts[0].length > 0 &&
                  (node.message.author.role !== "system"  || node.message.metadata.is_user_system_message)
              ) {
                  author = node.message.author.role;
                  if (author === "assistant") {
                      author = "ChatGPT";
                  } else if (author === "system" && node.message.metadata.is_user_system_message) {
                      author = "Custom user info"
                  }
                  messages.push({ author, text: node.message.content.parts[0] });
              }
              currentNode = node.parent;
          }
          return messages.reverse();
      }

      // on load, add messages to the root div
      window.onload = function() {
          var root = document.getElementById("root");
          for (var i = 0; i < jsonData.length; i++) {
              var conversation = jsonData[i];
              var messages = getConversationMessages(conversation);
              var div = document.createElement("div");
              div.className = "conversation";
              div.innerHTML = "<h4>" + conversation.title + "</h4>";
              for (var j = 0; j < messages.length; j++) {
                  var message = document.createElement("pre");
                  message.className = "message";
                  message.innerHTML = `<div class="author">${messages[j].author}</div><div>${messages[j].text}</div>`;
                  div.appendChild(message);
              }
              root.appendChild(div);
          }
      }
    </script>
  </head>
  <body>
    <div id="root"></div>
  </body>
</html>